Shanghai Henlius Biotech, Inc. (2696.HK)

HKD 40.35

(3.59%)

Operating Income Summary of Shanghai Henlius Biotech, Inc.

Shanghai Henlius Biotech, Inc.'s latest annual operating income in 2023 was 631.7 Million CNY , up 221.11% from previous year.
Shanghai Henlius Biotech, Inc.'s latest quarterly operating income in 2024 Q2 was 224.03 Million CNY , down 0.0% from previous quarter.
Shanghai Henlius Biotech, Inc. reported an annual operating income of -586.57 Million CNY in 2022, up 32.71% from previous year.
Shanghai Henlius Biotech, Inc. reported an annual operating income of -871.74 Million CNY in 2021, up 8.22% from previous year.
Shanghai Henlius Biotech, Inc. reported a quarterly operating income of 224.03 Million CNY for 2024 Q2, down 0.0% from previous quarter.
Shanghai Henlius Biotech, Inc. reported a quarterly operating income of 710.39 Million CNY for 2023 FY, up 221.11% from previous quarter.

Annual Operating Income Chart of Shanghai Henlius Biotech, Inc. (2023 - 2017)

Historical Annual Operating Income of Shanghai Henlius Biotech, Inc. (2023 - 2017)

Year	Operating Income	Operating Income Growth
2023	631.7 Million CNY	221.11%
2022	-586.57 Million CNY	32.71%
2021	-871.74 Million CNY	8.22%
2020	-949.85 Million CNY	-15.67%
2019	-821.2 Million CNY	-79.88%
2018	-456.52 Million CNY	-40.49%
2017	-324.95 Million CNY	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	224.03 Million CNY	15.58%
2024 Q2	224.03 Million CNY	0.0%
2023 FY	710.39 Million CNY	221.11%
2023 Q1	141.8 Million CNY	133.3%
2023 Q4	193.83 Million CNY	-11.01%
2023 Q3	217.81 Million CNY	53.6%
2023 Q2	141.8 Million CNY	0.0%
2022 Q4	-425.83 Million CNY	-1218.76%
2022 Q3	38.06 Million CNY	183.68%
2022 Q2	-45.48 Million CNY	0.0%
2022 Q1	-45.48 Million CNY	70.63%
2022 FY	-586.57 Million CNY	32.71%
2021 Q3	-154.87 Million CNY	12.87%
2021 Q2	-177.74 Million CNY	0.0%
2021 Q1	-177.74 Million CNY	23.35%
2021 FY	-871.74 Million CNY	8.22%
2021 Q4	-154.87 Million CNY	0.0%
2020 FY	-949.85 Million CNY	-15.67%
2020 Q4	-231.89 Million CNY	0.0%
2020 Q2	-230.57 Million CNY	0.0%
2020 Q1	-230.57 Million CNY	9.73%
2020 Q3	-231.89 Million CNY	-0.57%
2019 Q4	-255.43 Million CNY	0.0%
2019 Q2	-146.36 Million CNY	1.88%
2019 Q1	-149.16 Million CNY	-4.66%
2019 FY	-821.2 Million CNY	-79.88%
2019 Q3	-255.43 Million CNY	-74.52%
2018 Q4	-142.52 Million CNY	0.0%
2018 FY	-456.52 Million CNY	-40.49%
2018 Q3	-142.52 Million CNY	-17.81%
2018 Q2	-120.98 Million CNY	-163.74%
2018 Q1	-45.87 Million CNY	0.0%
2017 FY	-324.95 Million CNY	0.0%

Peer Operating Income Comparison of Shanghai Henlius Biotech, Inc.

Name	Operating Income	Operating Income Difference
Uni-Bio Science Group Limited	67.76 Million HKD	-832.157%
CK Life Sciences Int'l., (Holdings) Inc.	897.95 Million HKD	29.651%